DANIEL K SPIEGELMAN
CIK 1238403 · EVP, Chief Financial Officer · last filed 2026-06-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.94M
Companies
14
Total Filings
144
Lifetime Open-Market Net
-$34.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MAZE | Director | — | $24.05 | — | $0 | 2 | 2026-06-10 |
| SPRB | Director | — | $51.89 | — | $0 | 7 | 2026-05-26 |
| VTVT | Director | — | $32.77 | — | $0 | 2 | 2025-06-12 |
| KYTX | Director | 16,634 | $8.05 | $134.0K | $0 | 1 | 2025-06-02 |
| MYGN | Director | 32,917 | $4.33 | $142.5K | -$792.3K | 11 | 2024-06-07 |
| BMRN | EVP, Chief Financial Officer | 47,686 | $55.95 | $2.67M | -$30.78M | 59 | 2019-06-07 |
| Cascadian Therapeutics, Inc. (CASC) Delisted | Director | 21,006 | — | — | $0 | 4 | 2017-09-26 |
| Relypsa Inc (RLYP) Delisted | Director | 0 | — | — | -$19.6K | 4 | 2016-09-02 |
| Cascadian Therapeutics, Inc. (ONTY) Delisted | Director | 52,675 | — | — | $33.3K | 17 | 2015-09-28 |
| Anthera Pharmaceuticals Inc (ANTH) Delisted | Director | — | — | — | $0 | 5 | 2013-05-20 |
| AFFYMAX INC (AFFY) Delisted | Director | — | — | — | $0 | 6 | 2012-06-18 |
| OMER | Director | — | $8.73 | — | $0 | 3 | 2012-06-04 |
| Bio Green Med Solution, Inc. (CYCCP) Delisted | Director | — | $5.05 | — | $0 | 6 | 2012-05-24 |
| CV THERAPEUTICS INC (CVTX) Delisted | SVP, CFO | 74,458 | — | — | -$2.93M | 16 | 2009-04-17 |
Recent Filings · Page 5 of 15
144 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-13 | BMRN | Mixed | — | -$2.12M | EDGAR |
| 2017-09-26 | Cascadian Therapeutics, Inc. (CASC) Delisted | Mixed | +1,781 | -$2.3K | EDGAR |
| 2017-06-27 | Cascadian Therapeutics, Inc. (CASC) Delisted | Mixed | +6,793 | -$8.6K | EDGAR |
| 2017-06-13 | Cascadian Therapeutics, Inc. (CASC) Delisted | Mixed | +1,611 | -$1.8K | EDGAR |
| 2017-06-06 | BMRN | Tax (F) | −1,801 | -$163.4K | EDGAR |
| 2017-05-17 | BMRN | Mixed | −1,567 | -$146.7K | EDGAR |
| 2017-03-24 | BMRN | Grant (A) | +12,200 | $0 | EDGAR |
| 2017-03-17 | BMRN | Mixed | −6,290 | -$580.8K | EDGAR |
| 2017-03-08 | BMRN | Sell (S) | −2,303 | -$214.9K | EDGAR |
| 2017-03-07 | BMRN | Tax (F) | −2,283 | -$214.5K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.